Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCL

February 22nd 2021

Hun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.

Dr. Jain on the Safety Profile of Ibrutinib/Rituximab in MCL

February 20th 2021

Preetesh Jain, MD, PhD, discusses the safety profile of combination ibrutinib and rituximab in patients with mantle cell lymphoma.

Dr. Dean on the Potential Role of Consolidative CAR T-Cell Therapy in MCL

February 18th 2021

Robert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.

Dr. Ruan on the Future of Lenalidomide/Rituximab in MCL

February 17th 2021

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

Dr. Lee on the Potential Utility of Ibrutinib/Cirmtuzumab in MCL

February 16th 2021

Hun Ju Lee, MD, discusses the potential utility of ibrutinib in combination with cirmtuzumab in mantle cell lymphoma.

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

February 16th 2021

Venetoclax in Mantle Cell Lymphoma

February 16th 2021

Dr. Jain on the Efficacy of Ibrutinib/Rituximab in MCL

February 15th 2021

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib plus rituximab in mantle cell lymphoma.

Dr. Ruan on the Long-Term Benefits of Lenalidomide/Rituximab in MCL

February 12th 2021

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

Dr. Mehta on the Rationale for Utilizing Parsaclisib in Relapsed or Refractory MCL

February 12th 2021

Amitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.

BTK Inhibitors for Relapsed MCL: Important Considerations

February 9th 2021

Selecting a BTKi for Relapsed MCL Treatment

February 9th 2021

Acalabrutinib and Zanubrutinib for Relapsed MCL

February 2nd 2021

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

February 2nd 2021

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

January 26th 2021

Treatment Approaches in Mantle Cell Lymphoma

January 19th 2021

Accurately Diagnosing Mantle Cell Lymphoma

January 19th 2021

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

January 12th 2021

January 12, 2021 - Stopping combination treatment with venetoclax, lenalidomide, and rituximab after achieving minimal residual disease negativity in patients with relapsed/refractory mantle cell lymphoma is feasible.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.